Skip to main navigation

About us
- - - About us
      
      COMPASS Pathways is a mental health care company. We are dedicated to accelerating patient access to evidence-based innovation in mental health.
  - - About us
    - Our team
  - - Our stories
      
      Everyone has a mental health story, be it their own, or that of a friend or loved one. Our people bring their stories, and a wide range of backgrounds and skills to COMPASS.
      
      Read our stories
Our work
- - - Our work
      
      We want to find better ways to support people suffering with mental health challenges, and we believe we’re onto something important.
  - - COMPASS Pathways launches phase 2 clinical trial of psilocybin therapy in anorexia nervosa
      
      Multi-centre, double-blind randomised controlled phase 2 trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological treatment option.
      
      Read more
Join us
- - - Join us
      
      Here at COMPASS, we are united by our commitment to improving patient experience and outcomes in mental health care.
  - - Join us
  - - Our team
      
      Watch our team video to find out who we are and what defines us.
      
      Find out more
News & views
- - - News & views
      
      Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
  - - All news & views
  - - COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine
      
      Read more about our Phase 2b Study
Investors
- - - Investors
      
      We are COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
  - - News & events
    - Stock information
  - - Corporate governance
    - Investor resources
  - - COMP360 psilocybin therapy in TRD
      
      We have completed the largest randomised, controlled, double-blind psilocybin therapy study ever done.
      
      Read more
Impact
- - - Impact
      
      We are working to create positive impact by developing transformative therapies for those who are not helped by current treatments, by helping to build the mental health ecosystem of the future, and by acting responsibly as an organisation.
  - - Impact
  - - About us
      
      We have put a lot of thought into the kind of organisation we want to be, and make every decision with our four values in mind.
      
      Read more about us
LinkedIn
Youtube
Accessibility

Accessibility options

High Contrast
Greyscale
Negative Contrast
Readable
Reset

Search for news

News releases

Investor home
News & events
Stock information
Corporate governance
Investor resources

News releases

More news releases are coming soon.

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Print page Email alerts RSS feeds

Investor Relations
News & Events
News releases

This website is powered by renewable energy

Useful links

Contact us
About psilocybin therapy
About us
Join us
News & views

LinkedIn
Youtube

Unsolicited Information Policy
Terms
Privacy
myPathfinder privacy

This site uses functional cookies and external scripts to improve your experience.

More information

Privacy Settings More Information Functional Strictly Necessary Cookies

Privacy Settings

This site uses functional cookies and external scripts to improve your experience. Which cookies and scripts are used and how they impact your visit is specified on the left. You may change your settings at any time. Your choices will not impact your visit.

NOTE: These settings will only apply to the browser and device you are currently using.

More Information

If you would like to know more about Cookie Notices and Cookie Consent click here

Functional

These cookies are required for basic site functionality and are therefore always enabled. These include cookies that allow you to be remembered as you explore the site within a single session or, if you request, from session to session. They help make the shopping cart and checkout process possible as well as assist in security issues and conforming to regulations.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but if you do so, some parts of the site will not work. These cookies do not store any personal information.

You are now leaving COMPASS Pathways’ website.

COMPASS does not control and is not responsible for the content on the website you are about to visit. COMPASS is providing this link as a convenience, and this link does not imply COMPASS endorsement of any material on the website you are about to visit. Do you wish to continue?

No Yes

About us

Our work

COMPASS Pathways launches phase 2 clinical trial of psilocybin therapy in anorexia nervosa

Join us

Our team

News & views

Investors

COMP360 psilocybin therapy in TRD

Impact

About us

News releases

News releases

You are now leaving COMPASS Pathways’ website.